Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Expert Guidance on Optimizing Treatment Strategies for Acute Lymphoblastic Leukemia
  • CME
  • CE

Amir Fathi, MD
Released: April 16, 2020

Overview of Induction Regimens for ALL

Pediatric vs Adult Regimens for ALL

In recent years, there have been attempts to use more intensive chemotherapy, inspired by those used in pediatric patients, in adolescent and young adult (AYA) patients with B‑cell ALL. These regimens derived from pediatric protocols include more intensive use of corticosteroids, vincristine, as well as asparaginase.[13] They also emphasize timely administration of therapy with less time between treatment cycles and use MRD quantification to determine the next steps of therapy. The pediatric-inspired regimens have been studied by a variety of groups in the United States and Europe and have consistently demonstrated better outcomes than conventional adult regimens in AYA patients.[14]

A typical regimen for ALL consists of induction therapy, consolidation or early intensification, an interim maintenance phase, a course of delayed intensification, followed by another consolidation and a final prolonged course of maintenance. As mentioned, pediatric regimens involve more intensive use of corticosteroids, vincristine, and asparaginase. Therefore, these regimens are usually quite intensive upfront and prolonged, requiring a rigorous approach to maintain patients on schedule for therapy. For patients with Ph-positive diseases, a BCR/ABL tyrosine kinase inhibitor (TKI) is usually added to the various regimens.

Intergroup C10403: Pediatric-Like Regimen for AYA Patients With ALL

The Intergroup C10403 study examined a pediatric-like regimen in AYA patients with ALL.[14] Among 295 evaluable patients, the 3-year EFS rate was 59% with a median EFS of 78 months compared with historical control of 30 months. The 3-year OS rate was 73% and the median OS was not reached. These results represent very promising outcomes in this patient population, particularly compared with conventional regimens previously used in similar populations.

Rituximab Improves Outcome for CD20+ ALL

Other approaches to the treatment of ALL include the addition of targeted therapies such as rituximab to conventional therapies. A subset of patients with B‑cell ALL expresses the protein CD20 on the cell surface; consequently, rituximab, a CD20 antibody, has been combined with traditional chemotherapies for CD20-expressing B‑cell ALL. In a study conducted at the MD Anderson Cancer Center, 282 patients with CD20-positive B-cell ALL received hyper-CVAD plus rituximab.[15] Both CR duration and OS were significantly improved by the addition of rituximab to hyper-CVAD.

Inotuzumab Ozogamicin Plus Mini-Hyper-CVD as Frontline Therapy in Patients Older Than 60 Years of Age

More recently, InO, an ADC targeting CD22, was combined with mini‑hyper-CVD, a less intensive version of hyper-CVAD, in 52 patients older than 60 years of age with Ph-negative ALL in a single-arm phase II study.[16] Both the PFS and OS outcomes were quite promising with a 3-year OS rate of 56%, which compared favorably vs the historical values in patients treated with hyper-CVAD.[17]

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by educational grants from
Jazz Pharmaceuticals, Inc.
Pfizer Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?